CTNM ▼ -8.2% - Contineum Therapeutics, Inc. $CTNM - Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder Contineum Therapeutics fell 8.2% today following the release of Phase 2 results for its depression candidate JNJ-5120/PIPE-307. The stock's decline suggests investors viewed the efficacy or safety data as disappointing relative to expectations, though the headline does not specify the details of the trial outcome. 14-SEP-2026 04:13 PM ET